

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Afatinib for treating epidermal growth factor  
receptor mutation positive locally advanced or  
metastatic non-small cell lung cancer**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final Appraisal Determination**

(no ACD was issued)

- |                                                                                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|
| 1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how? |
|-------------------------------------------------------------------------------------------------------------------------------|

A potential equality issue was raised at the scoping workshop regarding the availability of timely EGFR testing to influence first line therapy. However, this was not considered to be an equalities issue that could be addressed by the recommendations in the guidance, and therefore was not considered by the Committee.
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

- |                                                                                                                                                                      |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

No.
-----

- |                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------|

No.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the Committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

The summary table notes that no equality and diversity issues relating to population groups protected by equality legislation were highlighted when the scope for this appraisal was developed, or during the appraisal.

**Approved by Programme Director (name):** Meindert Boysen

**Date:** 23/04/2014

Technology appraisals: Guidance development  
Equality impact assessment for the single technology appraisal of Afatinib for treating epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer  
Issue date: April 2014